SOURCE: Paragon Financial Limited
NEW YORK, NY--(Marketwire - Jul 25, 2012) - The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Celldex Therapeutics, Inc. (NASDAQ: CLDX) and ImmunoCellular Therapeutics Ltd. (NYSE: IMUC).
Access to the full company reports can be found at:
Despite having to negotiate a more challenging regulation process, biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets, human monoclonal antibodies, and immune modulators as precision delivered therapeutic agents for the treatment of cancer, infectious and inflammatory diseases.
ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies for the treatment of brain cancer, and other cancers. The company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: